Background: Mesenchymal stem cells (MSCs) have emerged as living biodrugs for myocardial repair and regeneration. Recent randomized controlled trials (RCTs) have reported that MSC-based therapy is safe and effective in heart failure patients; however, its dose-response relationship has yet to be established. We aimed to determine the optimal MSC dose for treating HF patients with reduced ejection fraction (EF) (HFrEF).
Methods: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) and Cochrane Handbook guidelines were followed. Four databases and registries, i.e., PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other websites, were searched for RCTs. Eleven RCTs with 1098 participants (treatment group, n = 606; control group, n = 492) were selected based on our inclusion/exclusion criteria. Two independent assessors extracted the data and performed quality assessments. The data from all eligible studies were plotted for death, major adverse cardiac events (MACE), left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and 6-minute walk distance (6-MWD) as safety, efficacy, and performance parameters. For dose-escalation assessment, studies were categorized as low-dose (< 100 million cells) or high-dose (≥ 100 million cells).
Results: MSC-based treatment is safe across low and high doses, with nonsignificant effects. However, low-dose treatment had a more significant protective effect than high-dose treatment. Subgroup analysis revealed the superiority of low-dose treatment in improving LVEF by 3.01% (95% CI; 0.65-5.38%) compared with high-dose treatment (-0.48%; 95% CI; -2.14-1.18). MSC treatment significantly improved the 6-MWD by 26.74 m (95% CI; 3.74-49.74 m) in the low-dose treatment group and by 36.73 m (95% CI; 6.74-66.72 m) in the high-dose treatment group. The exclusion of studies using ADRCs resulted in better safety and a significant improvement in LVEF from low- and high-dose MSC treatment.
Conclusion: Low-dose MSC treatment was safe and superior to high-dose treatment in restoring efficacy and functional outcomes in heart failure patients, and further analysis in a larger patient group is warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11170815 | PMC |
| http://dx.doi.org/10.1186/s13287-024-03713-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Serum Uric Acid Level With Bone Mineral Density and the Risk of Osteoporosis: A Dose-Response Meta-Analysis.
Int J Rheum Dis
January 2025
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Objective: Serum uric acid (SUA) may play positive roles in diseases associated with oxidative stress, such as osteoporosis (OP). Nevertheless, the specific impact of SUA levels on both bone mineral density (BMD) and the risk of OP remains uncertain. Considering such information crucial for clinicians when making decisions about urate-lowering therapy (ULT), we sought to fill this gap by conducting dose-response meta-analyses.
View Article and Find Full Text PDFHigh cumulative glucocorticoid dose is associated with increased levels of inflammation-related mediators in active rheumatoid arthritis.
Front Immunol
January 2025
Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital, Olomouc, Czechia.
Introduction: Glucocorticoids (GCs) are widely used as a treatment for rheumatoid arthritis (RA), leading to high cumulative doses in long-term treated patients. The impact of a high cumulative GC dose on the systemic inflammatory response in RA remains poorly understood.
Methods: We investigated long-treated patients with RA (n = 72, median disease duration 14 years) through blood counts and the serum levels of 92 inflammation-related proteins, and disease activity was assessed using the Simple Disease Activity Index (SDAI).
Dose-Response Effects of Exercise and Testosterone Replacement Therapy on Body Composition, Lean Mass, and Heart Rate Responses: A Case Report Using Wearable Technology.
Cureus
December 2024
College of Health Care Sciences, Nova Southeastern University, Fort Lauderdale, USA.
The case report explores the effects of testosterone replacement therapy (TRT) on body composition, lean muscle mass, and fat mass, based on the dosage of TRT and exercise intensity in a 40-year-old male. The purpose of this case study was to evaluate the dose-response relationship of TRT and exercise on muscle hypertrophy and fat loss over an eight-month period, using a validated wrist-worn wearable fitness tracker to measure daily physical activity and heart rate (HR)-based exercise intensity. The patient, a trained male with 25 years of consistent exercise experience, reported notable declines in strength and increases in body fat despite maintaining a regular workout routine.
View Article and Find Full Text PDFImmunogenicity and safety of the fourth dose of quadrivalent human papillomavirus (HPV) vaccine in immunosuppressed women who did not seroconvert after three doses.
Front Cell Infect Microbiol
January 2025
Departamento de Infectologia e Medicina Tropical, Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.
Introduction: Immunocompromised persons have high risk of persistent human papillomavirus (HPV) infection and HPV-related diseases, and lower immune response to vaccines. This study evaluated the immunogenicity and safety of administering a fourth dose of quadrivalent (4v)HPV vaccine in immunosuppressed women who did not seroconvert after three doses.
Methods: An open-label, not-controlled trial included immunosuppressed women (solid organ transplant patients and women receiving treatment for SLE) who did not seroconvert to at least one of the four HPV vaccine types after three 4vHPV vaccine doses.
Psoriasis and dementia: A population-based matched cohort study of adults in England.
Ann Clin Transl Neurol
January 2025
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Objective: Evidence for an association between psoriasis and dementia is limited and conflicting. We aimed to investigate the association using large and representative population-based data and describe risk by dementia subtype and over time.
Methods: We compared dementia risk between people with and without psoriasis using an age-, sex- and primary care practice-matched cohort of adults aged ≥40 years from the Clinical Practice Research Datalink Aurum in England (1997-2021) linked to hospital admissions data, analysed with stratified Cox regression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!